Mekinist and trametinib for HCC – pro
[The use of Dabrafenib/ Trametinib (DT) in HCC/cholangiocarcinoma is experimental/Investigational at this point. The largest clinically trial was that reported by Wainberg which included 33 patient with biliary tract cancer, of which 30 were confirmed to have Braf V600E mutation. This was an open phase II study. The ORR was 41%, PFS was 7.2 months with a med OS of 11.3. These results are encouraging but have not been studied againt the standard of care. "Biomarker analyses demonstrate a heterogeneous genetic landscape, and suggest a higher baseline expression of MAPK pathway genes in the pts who did not respond to D + T."
Wainberg ZA, Lassen UN, Elez E, et al: Efficacy and safety of dabrafenib and trametinib in patients with BRAF V600E–mutated biliary tract cancer: A cohort of the ROAR basket trial. 2019 Gastrointestinal Cancers Symposium.
NCCN Liver Cancer 20102